The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives

• Váldodahkkit: Alessandra Bracigliano (Dahkki), Antonella Lucia Marretta (Dahkki), Luigi Pio Guerrera (Dahkki), Roberto Simioli (Dahkki), Ottavia Clemente (Dahkki), Vincenza Granata (Dahkki), Anita Minopoli (Dahkki), Giuseppina Della Vittoria Scarpati (Dahkki), Fernanda Picozzi (Dahkki), Lucia Cannella (Dahkki), Antonio Pizzolorusso (Dahkki), Francesca Di Gennaro (Dahkki), Roberto Tafuto (Dahkki), Maria Rosaria Sarno (Dahkki), Ernesta Cavalcanti (Dahkki), Dario Ribera (Dahkki), Salvatore Tafuto (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2024-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Pheochromocytomas (PCCs) and Paragangliomas (PGLs), commonly known as PPGLs to include both entities, are rare neuroendocrine tumors that may arise in the context of hereditary syndromes or be sporadic. However, even among sporadic PPGLs, identifiable somatic alterations in at least one of the known...